(32) reported median OS of 20.4 months (95% CI, 10.8-not reached) for 53 patients, most with good performance status (85% ECOG PS 0–1), with EGFR/ALK/ROS1-wild-type advanced NSCLC, PD-L1 ≥50% who received first-line ICI plus platinum-based chemotherapy at Israeli cancer centers. Here, ROS1 is linked to non-small cell lung carcinoma.